Literature DB >> 23253743

Deletion 1q43 encompassing only CHRM3 in a patient with autistic disorder.

Andrea Klunder Petersen1, Ausaf Ahmad, Mustafa Shafiq, Brigette Brown-Kipphut, Chin-To Fong, M Anwar Iqbal.   

Abstract

Deletions on the distal portion of the long arm of chromosome 1 result in complex and highly variable clinical phenotypes which include intellectual disability, autism, seizures, microcephaly/craniofacial dysmorphology, corpus callosal agenesis/hypogenesis, cardiac and genital anomalies, hand and foot abnormalities and short stature. Genotype-phenotype correlation reported a minimum region of 2 Mb at 1q43-q44. We report on a 3 ½ year old male patient diagnosed with autistic disorder who has social withdrawal, eating problems, repetitive stereotypic behaviors including self-injurious head banging and hair pulling, and no seizures, anxiety, or mood swings. Array comparative genomic hybridization (aCGH) showed an interstitial deletion of 473 kb at 1q43 region (239,412,391-239,885,394; NCBI build37/hg19) harboring only CHRM3 (Acetylcholine Receptor, Muscarinic, 3; OMIM: 118494). Recently, another case with a de novo interstitial deletion of 911 kb at 1q43 encompassing three genes including CHRM3 was reported. The M3 muscarinic receptor influences a multitude of central and peripheral nervous system processes via its interaction with acetylcholine and may be an important modulator of behavior, learning and memory. We propose CHRM3 as a candidate gene responsible for our patient's specific phenotype as well as the overlapping phenotypic features of other patients with 1q43 or 1q43-q44 deletions.
Copyright © 2013. Published by Elsevier Masson SAS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23253743     DOI: 10.1016/j.ejmg.2012.11.003

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  6 in total

1.  Combined comparative genomic hybridization and single-nucleotide polymorphism array detects cryptic chromosomal lesions in both myelodysplastic syndromes and cytopenias of undetermined significance.

Authors:  Andrew G Evans; Ausaf Ahmad; W Richard Burack; M Anwar Iqbal
Journal:  Mod Pathol       Date:  2016-07-08       Impact factor: 7.842

2.  Subchronic treatment of donepezil rescues impaired social, hyperactive, and stereotypic behavior in valproic acid-induced animal model of autism.

Authors:  Ji-Woon Kim; Hana Seung; Kyung Ja Kwon; Mee Jung Ko; Eun Joo Lee; Hyun Ah Oh; Chang Soon Choi; Ki Chan Kim; Edson Luck Gonzales; Jueng Soo You; Dong-Hee Choi; Jongmin Lee; Seol-Heui Han; Sung Min Yang; Jae Hoon Cheong; Chan Young Shin; Geon Ho Bahn
Journal:  PLoS One       Date:  2014-08-18       Impact factor: 3.240

Review 3.  Exploring the Validity of Valproic Acid Animal Model of Autism.

Authors:  Darine Froy N Mabunga; Edson Luck T Gonzales; Ji-Woon Kim; Ki Chan Kim; Chan Young Shin
Journal:  Exp Neurobiol       Date:  2015-12-16       Impact factor: 3.261

4.  Constitutional 763.3 Kb chromosome 1q43 duplication encompassing only CHRM3 gene identified by next generation sequencing (NGS) in a child with intellectual disability.

Authors:  Xiaofei Cheng; Qifang Yang; Jun Liu; Juan Ye; Huiying Xiao; Gaimei Zhang; Yuanyuan Pan; Xia Li; Ruifeng Hao; Yinfeng Li
Journal:  Mol Cytogenet       Date:  2019-04-17       Impact factor: 2.009

5.  A homozygous missense variant in CHRM3 associated with familial urinary bladder disease.

Authors:  Glenda M Beaman; Gabriella Galatà; Keng W Teik; Jill E Urquhart; Ali Aishah; James O'Sullivan; Sanjeev S Bhaskar; Katherine A Wood; Huw B Thomas; Raymond T O'Keefe; Adrian S Woolf; Helen M Stuart; William G Newman
Journal:  Clin Genet       Date:  2019-09-11       Impact factor: 4.438

6.  Comprehensive Profiling of Gene Expression in the Cerebral Cortex and Striatum of BTBRTF/ArtRbrc Mice Compared to C57BL/6J Mice.

Authors:  Shota Mizuno; Jun-Na Hirota; Chiaki Ishii; Hirohide Iwasaki; Yoshitake Sano; Teiichi Furuichi
Journal:  Front Cell Neurosci       Date:  2020-12-10       Impact factor: 5.505

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.